Hofstetten Solothurn, Switzerland

Christoph Imboden


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christoph Imboden: Innovator in Pharmaceutical Chemistry

Introduction

Christoph Imboden is a notable inventor based in Hofstetten Solothurn, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative processes for producing complex chemical compounds. His work is characterized by a commitment to high yields and chemical purity.

Latest Patents

Imboden holds a patent for a process related to the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives. This invention specifically focuses on the compound 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide, which is produced with very high chemical purity. The patent highlights the importance of this process in the pharmaceutical industry, where the quality of compounds is crucial for therapeutic applications. He has 1 patent to his name.

Career Highlights

Christoph Imboden is associated with Newron Pharmaceuticals S.p.a., a company dedicated to developing innovative treatments for central nervous system disorders. His role in the company has allowed him to apply his expertise in pharmaceutical chemistry to real-world challenges, contributing to the advancement of medical science.

Collaborations

Imboden has worked alongside talented professionals such as Wolfgang Skranc and Michael Wolberg. Their collaborative efforts have fostered an environment of innovation and creativity within the pharmaceutical sector.

Conclusion

Christoph Imboden's contributions to pharmaceutical chemistry exemplify the impact of innovative processes in drug development. His dedication to producing high-quality compounds continues to influence the industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…